Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

PhRMA Marketing Code Is Shifting Promotional Budgets To CME

  • News

Executive Summary

Forest expects to devote more resources to continuing medical education teleconferences as industry and the prescribing community come into compliance with new guidelines on promotional practices

You may also be interested in...



CME Accrediting Proposal Should Clearly Define Conflict Of Interest – PhRMA

The Accreditation Council for Continuing Medical Education's proposed guidelines should include a clear definition of conflict for CME providers, the Pharmaceutical Research & Manufacturers of America says

CME Accrediting Proposal Should Clearly Define Conflict Of Interest – PhRMA

The Accreditation Council for Continuing Medical Education's proposed guidelines should include a clear definition of conflict for CME providers, the Pharmaceutical Research & Manufacturers of America says

Drug Manufacturer Education Grants To Purchasers May Be Kickback, IG Says

Education and research grants to purchasers from pharmaceutical manufacturers may violate the anti-kickback statute, the HHS Inspector General's compliance guide contends

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS040739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By